Hapalosin 

Hapalosin is a multidrug resistance reversal agent and chemosensitizer with mild cytotoxicity against cancer cells. Hapalosin inhibits the ATP-dependent drug efflux pump function of P-glycoprotein and antagonizes multidrug resistance-associated proteins. Hapalosin reverses multidrug resistance mediated by P-glycoprotein and multidrug resistance-associated proteins, increases the intracellular accumulation of drugs transported by P-glycoprotein, and enhances the cytotoxicity of these drugs against cancer cells overexpressing P-glycoprotein. Hapalosin can be used in the research of multidrug-resistant cancers^[1][2].

Hapalosin (1-6 µg/mL; 48 h) reverses P-gp-mediated multidrug resistance (MDR) in MCF-7/ADR cells, with an EC₅₀ of 1 µg/mL; meanwhile, the compound has an IC₂₀ of 6 µg/mL for intrinsic cytotoxicity against these cells^[1].
Hapalosin (0.7-6 µg/mL; 48 h) reverses MRP-mediated multidrug resistance (MDR) in HL-60/ADR cells, with an EC₅₀ of 0.7 µg/mL; meanwhile, the IC₂₀ for its intrinsic cytotoxicity against these cells is 6 µg/mL^[1].
Hapalosin (60 min) effectively increases the intracellular accumulation of [³H]-Vinblastine (HY-13780) in MCF-7/ADR cells, indicating that it inhibits P-gp-mediated drug efflux^[1].
Hapalosin (20 μM; 90 min) increases the accumulation of [³H]-Vinblastine and [³H]-Paclitaxel (HY-B0015) in SKVLB1 cells by inhibiting the P-glycoprotein efflux pump; at a concentration of 20 μM, the accumulation of [³H]-Paclitaxel increases by 440% compared with the control group, while this compound does not affect drug accumulation in SKOV3 cells^[2].
Hapalosin (2.5-12.5 μM; 48 h) selectively enhances the cytotoxicity of chemotherapeutic drugs transported by P-glycoprotein against MCF-7/ADR cells at concentrations ≥ 2.5 μM, and completely reverses P-glycoprotein-mediated multidrug resistance to vinblastine in these cells at a concentration of 5 μM^[2].
Hapalosin exhibits cytotoxicity against KB, LoVo and MCF-7/ADR cells, with IC₅₀ values of 2.5 μg/mL, 2 μg/mL and 5-15 μM^[2], respectively.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

489.64

C₂₈H₄₃NO₆

159542-04-8

CN(C([C@@H](OC([C@H]([C@H](OC(C[C@H]1O)=O)CCCCCCC)C)=O)C(C)C)=O)[C@H]1CC2=CC=CC=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Dinh TQ, et al. Design, synthesis, and evaluation of the multidrug resistance-reversing activity of D-glucose mimetics of hapalosin. J Med Chem. 1998;41(6):981-987.  [Content Brief]

  [2]. Stratmann K, et al. Hapalosin, a cyanobacterial cyclic depsipeptide with multidrug-resistance reversing activity. The Journal of Organic Chemistry. 1994 Dec;59(24):7219-26.